Symbicort Forte Turbohaler

Symbicort Forte Turbohaler is a fixed-dose combination therapy developed by AstraZeneca for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). It contains two active ingredients: budesonide, an inhaled corticosteroid (ICS), and formoterol fumarate dihydrate, a long-acting beta2-adrenergic agonist (LABA). Budesonide acts as an anti-inflammatory agent by binding to glucocorticoid receptors, thereby reducing airway inflammation and hyperresponsiveness. Formoterol serves as a potent bronchodilator by stimulating beta2-adrenergic receptors, leading to the relaxation of airway smooth muscle and improved airflow. The 'Forte' designation specifically refers to the 320/9 mcg dose strength delivered via the Turbohaler dry powder inhaler device. Clinical research, including studies conducted by University Hospital, Antwerp, has utilized advanced techniques like Computational Fluid Dynamics (CFD) to evaluate the drug's regional deposition and acute physiological effects on upper airway dimensions in severe COPD patients.

Brand names

SymbicortSymbicort Forte TurbohalerSymbicort Turbohaler

Other names

budesonide + formoterol fumarate dihydratebudesonide/formoterol